Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Sunshine Biopharma Inc. Warrant (SBFMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/22/2025: SBFMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/22/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.96 | 52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 |
52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.88% | Operating Margin (TTM) -14.56% |
Management Effectiveness
Return on Assets (TTM) -11.78% | Return on Equity (TTM) -21.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4553895 |
Shares Outstanding - | Shares Floating 4553895 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sunshine Biopharma Inc. Warrant
Company Overview
History and Background
Sunshine Biopharma Inc. Warrant does not have a standalone history as it is a derivative instrument tied to the performance of Sunshine Biopharma Inc. (SBFM). The warrants themselves represent the right to purchase shares of SBFM at a specified price within a given timeframe. The history of the warrants is directly linked to the corporate actions and stock performance of Sunshine Biopharma Inc. Sunshine Biopharma Inc. itself is a biopharmaceutical company focused on developing novel cancer and antiviral therapies. Significant milestones for the company would include clinical trial progress, regulatory filings, and strategic partnerships, all of which would indirectly impact the value and activity of its warrants.
Core Business Areas
- Sunshine Biopharma Inc. (Underlying Company): Development and commercialization of novel pharmaceuticals, primarily focusing on oncology and antiviral treatments. Their pipeline includes lead drug candidates like Adva-27a for pancreatic cancer and other cancers, as well as a potential COVID-19 treatment.
Leadership and Structure
The leadership and structure information pertains to Sunshine Biopharma Inc. (SBFM), the issuer of the warrants. As a publicly traded company, it has a Board of Directors and an executive management team responsible for its operations and strategic direction. Specific details on current leadership can be found in their SEC filings and corporate website.
Top Products and Market Share
Key Offerings
- Adva-27a (Underlying Company Product): Adva-27a is a novel small molecule anticancer drug targeting topoisomerase II. It is in development for various cancers, with a focus on pancreatic cancer. Market share data for such an early-stage drug is not yet applicable. Competitors in the pancreatic cancer space include established chemotherapy regimens and emerging targeted therapies. Competitors for antiviral therapies are numerous and depend on the specific virus.
- Other Pipeline Candidates (Underlying Company): Sunshine Biopharma Inc. also has other drug candidates in various stages of development. These could include other oncology drugs or antiviral agents. Market share and competitor information are highly specific to each therapeutic area and drug candidate.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, stringent regulatory oversight, and significant market potential for successful therapies. It is a highly competitive landscape with constant innovation and the emergence of new treatments for various diseases, including cancer and infectious diseases. The market is driven by unmet medical needs, advancements in scientific research, and the growing global demand for healthcare solutions.
Positioning
Sunshine Biopharma Inc. operates as a clinical-stage biopharmaceutical company with a focus on developing novel therapies. Its positioning is as an innovator in niche areas of oncology and antiviral research. Its competitive advantages would lie in the unique mechanisms of action of its drug candidates, if proven effective and safe in clinical trials, and potentially faster development pathways for certain indications. However, as a smaller company, it faces competition from larger, well-established pharmaceutical giants with greater resources for R&D, clinical trials, and commercialization.
Total Addressable Market (TAM)
The TAM for oncology drugs is in the hundreds of billions of dollars globally, and the antiviral market is also substantial and growing, especially considering the potential for future pandemics. Sunshine Biopharma Inc.'s TAM is defined by the specific indications their drug candidates target. For example, the TAM for pancreatic cancer treatments is significant but highly competitive. The company is positioned to capture a portion of this TAM if its lead drug candidates achieve regulatory approval and demonstrate efficacy.
Upturn SWOT Analysis
Strengths
- Focus on novel drug candidates with potentially unique mechanisms of action.
- Dedicated research and development team with expertise in oncology and antiviral therapeutics.
- Potential for significant market impact if clinical trials are successful.
Weaknesses
- Clinical-stage company with no approved products on the market.
- Limited financial resources compared to large pharmaceutical companies.
- High risk associated with drug development and clinical trial failures.
- Dependence on successful fundraising and partnerships.
Opportunities
- Unmet medical needs in oncology and antiviral treatment areas.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in biotechnology and personalized medicine.
- Growing demand for innovative healthcare solutions.
Threats
- Failure of clinical trials, leading to significant setbacks or discontinuation of drug development.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Regulatory hurdles and lengthy approval processes.
- Changes in healthcare policies and reimbursement landscapes.
- Economic downturns impacting R&D funding and investment.
Competitors and Market Share
Key Competitors
- Novartis (NVS)
- Pfizer (PFE)
- Merck & Co. (MRK)
- Bristol Myers Squibb (BMY)
- Roche Holding AG (RHHBY)
Competitive Landscape
Sunshine Biopharma Inc. faces a highly competitive landscape. Its main advantage lies in its targeted approach to specific cancer types and potential for novel drug mechanisms. However, it lacks the established infrastructure, extensive drug portfolios, and vast financial resources of larger pharmaceutical companies. Competitors have a significant advantage in terms of R&D funding, clinical trial execution, regulatory expertise, and global marketing and distribution capabilities. Sunshine Biopharma Inc.'s success hinges on the distinct efficacy and safety profiles of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historically, Sunshine Biopharma Inc.'s growth trajectory has been tied to its ability to advance its drug candidates through various stages of clinical development and to secure necessary funding. Progress in clinical trials and successful fundraising rounds would be considered key indicators of growth.
Future Projections: Future projections are highly speculative and contingent on the success of its clinical trials and regulatory approvals. Analyst estimates, if available, would focus on potential market penetration and revenue forecasts for approved drugs. The success of Adva-27a in clinical trials is a major factor influencing future growth.
Recent Initiatives: Recent initiatives likely involve advancing its lead drug candidates (like Adva-27a) through clinical trials, seeking strategic partnerships, and potentially engaging in further fundraising activities to support its research and development pipeline.
Summary
Sunshine Biopharma Inc. Warrant is a high-risk, high-reward investment tied to the success of Sunshine Biopharma Inc.'s drug development pipeline. The company shows promise with its novel oncology and antiviral candidates, particularly Adva-27a. However, it faces significant challenges due to its clinical-stage status, limited resources, and intense competition within the biopharmaceutical industry. Success hinges critically on positive clinical trial outcomes and regulatory approvals. Investors should be aware of the inherent volatility and the substantial risks involved.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Sunshine Biopharma Inc. SEC Filings (10-K, 10-Q)
- Industry reports on oncology and antiviral markets
- Financial data aggregators (e.g., Yahoo Finance, Google Finance)
- Pharmaceutical news outlets
Disclaimers:
This information is for informational purposes only and does not constitute financial or investment advice. The analysis is based on publicly available data and market conditions, which can change rapidly. Investing in warrants and clinical-stage biopharmaceutical companies involves significant risk, including the potential loss of principal. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc. Warrant
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2022-02-15 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.